Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients

Abstract

The tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR), such as osimertinib and gefitinib, aumolertinib have been widely used in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. However, the discrepancy of pharmacokinetic features and distributions in important tissues between these EGFR-TKIs remains obscure. In this study, an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method with specificity and accuracy was established. After a single equivalent dose ratio or equal dose gavage, aumolertinib displayed the shortest elimination half-life time (t_1/2), while it showed the largest area under the concentration-time curve in mouse plasma and bone marrow among these 3 EGFR-TKIs. Furthermore, at the time of reaching maximum concentration (t_max) after single equivalent dose ratio gavage, the concentrations of aumolertinib were significantly higher than that of osimertinib and gefitinib in 9 important tissues of mice. Moreover, after single oral administration, aumolertinib displayed the highest concentration in plasma samples from EGFR mutation-positive NSCLC patients. Collectively, our findings manifest that the bioavailability and tissue distribution features of aumolertinib are superior to those of osimertinib and gefitinib, providing a pharmacokinetic basis for the clinical application of aumolertinib and the development of next-generation EGFR-TKIs.

Keywords

aumolertinib / EGFR-TKIs / gefitinib / non-small cell lung cancer / osimertinib / pharmacokinetics

References

[1] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2] DeardenS, Stevens J, WuYL, BlowersD. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371-2376.

[3] WestoverD, Zugazagoitia J, ChoBC, LovlyCM, Paz-Ares L. Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(Suppl 1):i10-i19.

[4] RosellR, MoranT, QueraltC, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.

[5] WangZ, XingY, LiB, LiX, LiuB, WangY. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed. 2022;3(1):42.

[6] MaemondoM, InoueA, KobayashiK, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.

[7] WangS, CangS, LiuD. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.

[8] RemonJ, SteuerCE, RamalingamSS, FelipE. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29(Suppl 1):i20-i27.

[9] YangJC-H, Camidge DR, YangC-T, et al. Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial. J Thorac Oncol. 2020;15(12):1907-1918.

[10] WangJ, WuL. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opin Pharmacother. 2022;23(6):647-652.

[11] ZhangY, ZhangY, NiuW, et al. Experimental study of almonertinib crossing the blood-brain barrier in EGFR-mutant NSCLC brain metastasis and spinal cord metastasis models. Front Pharmacol. 2021;12:750031.

[12] ShirleyM, KeamSJ. Aumolertinib: a review in non-small cell lung cancer. Drugs. 2022;82(5):577-584.

[13] NagasakaM, ZhuVW, LimSM, Greco M, WuF, OuSHI. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+NSCLC. J Thorac Oncol. 2021;16(5):740-763.

[14] LiuL, LiW, YangL, et al. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers. Acta Pharmacol Sin. 2022;43(4):1082-1090.

[15] ZhouP, ChenG, GaoM, WuJ. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. Bioorg Med Chem. 2018;26(23-24):6135-6145.

[16] CurrieGM. Pharmacology, part 2: introduction to pharmacokinetics. J Nucl Med Technol. 2018;46(3):221-230.

[17] Mohd ZaffarinAS, NgS-F, NgMH, et al. Pharmacology and pharmacokinetics of vitamin E: nanoformulations to enhance bioavailability. Int J Nanomed. 2020;15:9961-9974.

[18] LiuL, YangL, LiW, ChenX. Simultaneous determination of almonertinib and its active metabolite HAS-719 in human plasma by LC-MS/MS: evaluation of pharmacokinetic interactions. Journal of Chromatography B. 2022;1197:123231.

[19] YingZ, WeiJ, LiuR, ZhaoF, YuY, TianX. An UPLC-MS/MS method for determination of osimertinib in rat plasma: application to investigating the effect of ginsenoside Rg3 on the pharmacokinetics of osimertinib. Int J Anal Chem. 2020;2020:8814214.

[20] ZhengX, WangW, ZhangY, et al. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. Biomed Chromatogr. 2018;32(12):e4365.

[21] ZhengN, ZhaoC, HeXR, et al. Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. J Chromatogr B. 2016;1011:215-222.

[22] WuL, ZhongW, LiA, et al. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. Ann Transl Med. 2021;9(11):950.

[23] ZhangQ, LiuH, YangJ. Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced cardiotoxicity: case report and review. Front Endocrinol. 2022;13:833929.

[24] WeiY, CuiY, GuoY, LiL, ZengL. A lung adenocarcinoma patient with a rare EGFR E709_T710delinsD mutation showed a good response to afatinib treatment: a case report and literature review. Front Oncol. 2021;11:700345.

[25] ZhuQ, JiangM, LiW, et al. A lung cancer patient harboring a rare oncogenic EGFR exon 20 V786M mutation responded to a third-generation tyrosine kinase inhibitor: case report and review of the literature. Front Oncol. 2022;12:912426.

[26] ChenN, ZhouS, PalmisanoM. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56(2):139-152.

[27] LiuL. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15-32.

[28] TengZ, YuM, DingY, et al. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. Int J Nanomedicine. 2018;14:119-133.

[29] BrennanCW, Verhaak RGW, McKennaA, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.

[30] EngleDD, TiriacH, RiveraKD, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019;364(6446):1156-1162.

[31] BertottiA, PappE, JonesS, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263-267.

[32] HouZ, WuH, LuoN, et al. Almonertinib combined with anlotinib and temozolomide in a patient with recurrent glioblastoma with EGFR L858R mutation. Oncologist. 2023;28(5):449-452.

[33] ZhuY, LiuC, XuZ, et al. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis. Chin Med J (Engl). 2023;136(21):2551-2561.

[34] LiP, ZhaoL. Developing early formulations: practice and perspective. Int J Pharm. 2007;341(1-2):1-19.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).